Navigation Links
IU Personalized Medicine Institute to develop targeted and individualized treatments
Date:2/9/2011

enable informatics and the School of Informatics to play a significant role in the success of the institute."

"This science will enable physicians to prescribe the right medicines at the right dosages and intervals to maximize efficacy and prevent unwanted toxicity. It should be a very exciting next 10 years of research," said D. Wade Clapp, M.D., chairman of the Department of Pediatrics.

"Personalized medicine will make a significant and immediate impact in the care of patients with heart diseases," said Peng-Sheng Chen, M.D., director of the Krannert Institute of Cardiology.

In addition to Flockhart, the institute's leadership will include associate directors Lang Li, Ph.D., associate professor of medical and molecular genetics and associate director of the IU Center for Computational Biology and Bioinformatics; Jamie L. Renbarger, M.D., assistant professor of pediatrics, of medicine and of obstetrics and gynecology; and Bryan Schneider, M.D., assistant professor of medicine and of medical and molecular genetics.

The institute's mission is to conduct research, train new specialists in personalized medicine and promote the translation of scientific discoveries into new more precise therapeutics for patient care.

Training new experts will be supported by the new Brater Scholarship in Personalized Medicine, which will provide funds for research to young physicians in medical fellowship training programs at the school of medicine. The first three fellows to receive Brater scholarships will be selected this summer.

To help move scientific discoveries to patient bedsides, the institute will have a panel of IU scientists who will advise researchers on steps to take to move their research beyond the laboratory stages. The advisory panel, with 21 members initially, will be chaired by Dr. Clapp.

The institute also has an external advisory board with five members:

  • Caryn Lerman, Ph.D., Mary W. Cal
    '/>"/>

Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Tufts University calls for moderate approach to teaching personalized genomic testing
2. Personalized molecular therapy shows promising results for people with advanced lung cancer
3. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
4. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
5. New venture explores frontiers of personalized medicine
6. Personalized treatment may help some liver cancer patients
7. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
8. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
9. Personalized medicine: Molecular imaging predicts treatment success in many cancers
10. Pilot study supports adolescent diabetes patients through personalized text messages
11. Tumor target suggests personalized treatment for melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Medical Ministry International announced today that ... by GreatNonprofits , the leading provider of user reviews ... a Top-Rated 2013 Nonprofit,” says Samuel Smith, MMI CEO. ... 3000 Volunteers and Staff serving in 22 countries around the ... those that have seen our work first hand and wanted ...
(Date:5/21/2013)... on a large scale is the cornerstone of ... better outcomes, better value and better experience of ... patient-centered medical home model offers a viable solution ... of Health and Human Services, Agency for Healthcare ... more about the processes and determinants of successful ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 Mecklenburg ... Charlotte will hold a free Community Wellness Fair to ... The fair will be held on Wednesday, May 22, ... University City YMCA (8100 Old Mallard Creek Road, Charlotte, ... American Heart Association and the Mecklenburg County Department ...
(Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
(Date:5/21/2013)... 2013 The In View series ... and cable channels across the country, announces it has ... channel. The producers of the series proudly bring audiences ... industry, the manufacturing industry, health-related companies, medical facilities and ... medical practitioners in all parts of the United States, ...
Breaking Medicine News(10 mins):Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2
... Tobacco-Free,Kids, WASHINGTON, Oct. 2 The following is ... Kids:, The Campaign for Tobacco-Free Kids applauds Tyra ... exposing the ugly truth that,smoking is not only dangerous ... week,s season premiere of "America,s Next Top Model",featured a ...
... Manchester scientists will discuss their research aimed at reducing ... at the National Cancer Research Institute conference in Birmingham ... patients receive radiotherapy as part of their cancer treatment ... causing side effects (toxicity) to the normal tissues and ...
... For the first time, data show a positive ... overall health at birth. Babies born to women with ... to be less likely to need intensive care than ... Inc. (NASDAQ:CBRX) announced today. The data are published in ...
... Angel Flight West (AFW),awarded The Distinguished Pilot award ... Awards on Saturday, September 29. Dr. Irish,completed 18 Angel ... AFW,pilot, he flies people in need whose non-emergency health ... facilities. Dr. Irish, like,all AFW volunteer pilots, donates the ...
... Does your October purchase really make a difference?, ... products to,benefit the breast cancer cause, Y-ME National Breast ... make meaningful,consumer choices to ensure that their money really ... consumers can take to become informed about,pink, promotions so ...
... HILL, N.C., Oct. 2 The U.S. hospital ... vying to get their,therapies on hospital formularies. Among ... time with key physicians and the list of ... companies are working their way into formularies via,specialized ...
Cached Medicine News:Health News:Tobacco-Free Kids Applauds Tyra Banks for Exposing the Ugly Truth About Smoking 2Health News:Cancer researchers seek safe reduction of radiotherapy 2Health News:Vaginal progesterone gel may improve infant outcomes and... 2Health News:Vaginal progesterone gel may improve infant outcomes and... 3Health News:Vaginal progesterone gel may improve infant outcomes and... 4Health News:Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards 2Health News:National Breast Cancer Awareness Month 2Health News:Equipping your Sales Force to Influence Hospital Formulary Decision-Makers 2
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...
... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... panels mounted on powder-coated steel ... free-standing modular cleanroom that meets ... Optional ceiling HEPA filter/fan units, ... to customer requirements. Negative-pressure ventilation, ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: